VADER
22 Feb 2023
Trial Summary
A phase II randomised controlled trial to determine the efficacy of combining the HDAC inhibitor sodium valproate with EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic colorectal cancer (VADER study).
Acronym:
VADER
ACTRN/NCT /ethics:
–
Scientific title:
–
Sponsor / Cooperative group:
GI Cancer
Trial & Patient Characteristics
| Cancer Type | Colorectal |
|---|---|
| Trial Type | Interventional |
| Phase | Phase II |
| Age Range | 18 Years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-01-23 |
| Anticipated End Date | 2024-06-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Chris Karapetis |
| Recruitment Status | Recruiting |